Astragaloside II enhanced sensitivity of ovarian cancer cells to cisplatin via triggering apoptosis and autophagy.
Lijia ZhangYe LiuXue LeiXiaowai LiuHeng SunSongjiang LiuPublished in: Cell biology international (2023)
Cisplatin (DDP) based chemotherapy occurs a reduced therapeutic effect on the later treatment of ovarian cancer (OC) due to DDP resistance. Astragaloside II (ASII), a natural product extracted from Radix Astragali, has shown promising anticancer effects. However, the effects of ASII on OC have not been clarified. In this study, we found that ASII inhibited cell growth and promoted cell apoptosis of DDP-resistant OC cells in vitro and in vivo. Further study showed that ASII downregulated multidrug resistance-related protein MDR1 and cell cycle-related protein Cyclin D1 and PCNA, and also upregulated apoptosis-related protein leaved PRAP and cleaved caspase-3. In addition, ASII induced autophagy, characterized by upregulation of LC3II expression, downregulation of p62 expression, and elevation of LC3 punctuation, may be associated with inhibition of the AKT/mTOR signaling pathway. Moreover, the messenger RNA-sequencing was used to identify potential molecules regulated by ASII. In conclusion, these findings indicated that ASII increased sensitivity of DDP in the treatment of OC.
Keyphrases
- signaling pathway
- cell cycle arrest
- cell cycle
- cell proliferation
- cell death
- induced apoptosis
- endoplasmic reticulum stress
- pi k akt
- oxidative stress
- poor prognosis
- single cell
- squamous cell carcinoma
- risk assessment
- diabetic rats
- multidrug resistant
- combination therapy
- epithelial mesenchymal transition
- locally advanced
- human health
- high glucose
- long non coding rna
- climate change